Multicenter Atrial fibrillation Intervention Keeps innOvating registry

Multicenter Atrial fibrillation Intervention Keeps innOvating registry - MAIKO registry

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050200005

Enrollment

3000

Registered

2020-04-23

Start date

2019-01-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation atrial fibrillation, cahteter ablation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing catheter ablation including PV isolation for symptomatic atrial fibrillation Patients who are over 20 years old Willing to sign the consent form for participation

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Atrial tachyarrhythmias lasting for > 30 seconds or requiring repeat ablation, hospital admission, cardioversion or antiarrhythmic drug (AAD) therapy* between 91 and 365 days after ablation.	—

Secondary

Measure	Time frame
1 Atrial tachyarrhythmias lasting for > 30 seconds or requiring repeat ablation, hospital admission, cardioversion or antiarrhythmic drug (AAD) therapy between 0 and 90 days after ablation. 2 Repeat Ablation for atrial tachyarrhythmias. 3 Atrial tachyarrhythmias lasting for > 30 seconds or requiring repeat ablation, hospital admission, cardioversion or AAD therapy after ablation. 4 Exacerbation of congestive heart failure (emergency admission or hospitalization) 5 Worsening renal function (reduction of eGFR >30%) 6 Stroke (Ischemic stroke and intracranial hemorrhage) 7 Quality of Life (QOL) score. 8:Biomarkers (TnI, CRP, CK, CKMB, NGAL, Cre, BNP, NT-pro BNP)	—

Measure

Time frame

1 Atrial tachyarrhythmias lasting for > 30 seconds or requiring repeat ablation, hospital admission, cardioversion or antiarrhythmic drug (AAD) therapy between 0 and 90 days after ablation. 2 Repeat Ablation for atrial tachyarrhythmias. 3 Atrial tachyarrhythmias lasting for > 30 seconds or requiring repeat ablation, hospital admission, cardioversion or AAD therapy after ablation. 4 Exacerbation of congestive heart failure (emergency admission or hospitalization) 5 Worsening renal function (reduction of eGFR >30%) 6 Stroke (Ischemic stroke and intracranial hemorrhage) 7 Quality of Life (QOL) score. 8:Biomarkers (TnI, CRP, CK, CKMB, NGAL, Cre, BNP, NT-pro BNP)

—

Contacts

Public ContactTetsuma Kawaji

Mitsubishi Kyoto Hospital

kawaji@kuhp.kyoto-u.ac.jp+81-75-381-2111

Outcome results